Issues in using progression-free survival when evaluating oncology products.
暂无分享,去创建一个
Thomas R Fleming | T. Fleming | H. Lu | M. Rothmann | Mark D Rothmann | Hong Laura Lu | Mark Rothmann
[1] Thomas R Fleming,et al. Surrogate endpoints and FDA's accelerated approval process. , 2005, Health affairs.
[2] Walter M Stadler,et al. Recommended changes to oncology clinical trial design: revolution or evolution? , 2008, European journal of cancer.
[3] D. Sargent,et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Daniel J Sargent,et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Marc Peeters,et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] P. Catalano,et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] K. Carroll,et al. Analysis of progression‐free survival in oncology trials: some common statistical issues , 2007, Pharmaceutical statistics.
[8] Boris Freidlin,et al. Proposal for the use of progression-free survival in unblinded randomized trials. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Marie Davidian,et al. Estimation of Survival Distributions of Treatment Policies in Two‐Stage Randomization Designs in Clinical Trials , 2002, Biometrics.
[10] B. Freidlin,et al. Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] M. Buyse,et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Thomas R Fleming,et al. Standard versus adaptive monitoring procedures: a commentary , 2006, Statistics in medicine.
[13] Thomas R Fleming,et al. Current issues in non‐inferiority trials , 2008, Statistics in medicine.
[14] D. DeMets,et al. Surrogate End Points in Clinical Trials: Are We Being Misled? , 1996, Annals of Internal Medicine.